We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities.
- Authors
Walker, Harry E.; Rizzo, Manfredi; Fras, Zlatko; Jug, Borut; Banach, Maciej; Penson, Peter E.
- Abstract
Elevated circulating concentrations of low-density lipoprotein cholesterol (LDL-C) have been conclusively demonstrated in epidemiological and intervention studies to be causally associated with the development of atherosclerotic cardiovascular disease. Enormous advances in LDL-C reduction have been achieved through the use of statins, and in recent years, through drugs targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of the hepatic LDL-receptor. Existing approaches to PCSK9 targeting have used monoclonal antibodies or RNA interference. Although these approaches do not require daily dosing, as statins do, repeated subcutaneous injections are nevertheless necessary to maintain effectiveness over time. Recent experimental studies suggest that clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing targeted at PCSK9 may represent a promising tool to achieve the elusive goal of a 'fire and forget' lifelong approach to LDL-C reduction. This paper will provide an overview of CRISPR technology, with a particular focus on recent studies with relevance to its potential use in atherosclerotic cardiovascular disease.
- Subjects
GENOME editing; LDL cholesterol; LIPIDS; SUBCUTANEOUS injections; MONOCLONAL antibodies; ATHEROSCLEROSIS; CRISPRS
- Publication
Metabolites (2218-1989), 2021, Vol 11, Issue 12, p857
- ISSN
2218-1989
- Publication type
Article
- DOI
10.3390/metabo11120857